Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.33 |
| ▸ | FBP1 | P09467 | 4/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836576 | 0.92 | ENPP1 (0.39) | EGFRENPP1RETERBB2 | |
| SCHEMBL2832536 | 0.91 | RET (0.43) | EGFRENPP1RETERBB2 | |
| SCHEMBL2836110 | 0.80 | P2RX7 (0.44) | EGFRENPP1ERBB2FBP1ERBB4 | |
| SCHEMBL10012996 | 0.77 | ENPP1 (0.37) | EGFRENPP1ERBB2FBP1 | |
| SCHEMBL2833476 | 0.76 | EGFR (0.39) | EGFRRETERBB2FBP1ERBB4 | |
| SCHEMBL13844442 | 0.73 | KIT (0.43) | EGFRENPP1RETERBB2FBP1 | |
| SCHEMBL2833438 | 0.72 | P2RX7 (0.43) | EGFRENPP1ERBB2ERBB4 | |
| SCHEMBL13091013 | 0.71 | ENPP1 (0.38) | EGFRENPP1RET | |
| SCHEMBL2834806 | 0.70 | EGFR (0.48) | EGFRERBB2ERBB4 | |
| SCHEMBL10012042 | 0.69 | ENPP1 (0.39) | EGFRENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | claimed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | claimed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | claimed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| WO-2009057139-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | EGFR 1213/4885ENPP1 2315/4885RET 1946/4885 |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | EGFR 1110/4885ENPP1 2397/4885RET 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.